You are using an older version of Internet Explorer that is not supported on this site. Please upgrade for the best experience.

Recent Externally Funded Research Awards

2016

4th Quarter (October-December 2016)

JERRY, JOSEPH

  • ROH Breast Cancer Center Funding
    240,000.00 BAYSTATE HEALTH, INC. RAYS OF HOPE 

JOHNSON, MD KARIN

  • Novel Scoring Method for Obstructive Sleep Apnea
    50,000.00 BAYSTATE HEALTH, INC. RPAP 

KAWAR, MD NADA

  • BPA and Phthalates: Effects on Inflammatory Markers in the Breast and Breast Density in Young Women
    68,095.00 UNIVERSITY OF MA/AMHERST NAT. INSTITUTES OF HEALTH (NIH) 

LINDENAUER, MD PETER

  • Yale New Haven Health Services FY17 Core Measure
    50,661.00 YALE NEW HAVEN HLTH SVCS CORP

MOORE, MD FRANKLIN

  • De-identified Residual Sample Collection and Testing of the Investigational GI Panel on the GenMark ePlex Platform
    13,500.00 GENMARK DIAGNOSTICS, INC. 

SCHMELKIN, MD IRA

  • Multicenter, prospective, randomized study comparing the diagnostic yield of colon capsule endoscopy versus computed tomographic colonography in a screening population (TOPAZ” Study)
    119,594.00 MEDTRONIC, INC. 

SCHNEIDER,PHD, SALLIE

  • Identification and harmonization of intermediate endpoints for environmental exposures
    60,075.00 UNIVERSITY OF WISCONSIN NAT. INSTITUTES OF HEALTH(NIH)

SHENBERGER, MD JEFFREY

  • NASCare: A mobile tool for diagnosis and treatment of neonatal abstinence syndrome
    5,000.00 DIMAGI INC. NAT INST ON DRUG ABUSE

SKIEST, MD DANIEL

  • GEMINI 1 - A Phase III, randomised, double-blind, multicentre, parallel- group, non-inferiority study evaluating the efficacy, safety, and tolerability of dolutegravir plus lamivudine compared to dolutegravir plus tenofovir/emtricitabine in HIV-1-infected treatment-naïve adults
    167,464.00 GLAXOSMITHKLINE

SUMMERS, MANDI

  • FY17 Child Passenger Safety (CPS) Training and administration Grant
    32,000.00 MA EXEC OFFICE PUBLIC SAFETY US DEPT OF HIGHWAY SAFETY

TIDSWELL, MD MARK

  • Randomized, Double-Blind, Parallel Group Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-936558 (nivolumab) in Participants with Severe Sepsis or Septic Shock
    56,376.00 BRISTOL-MYERS SQUIBB
  • Pilot study of non-invasive ventilatory support for acute hypoxemic respiratory failure: High flow nasal cannula vs. Helmet vs. Mask
    49,997.00 BAYSTATE HEALTH, INC. RPAP

TIRABASSI, MD MICHAEL

  • Evaluation of AntiGD2-PolyMPC−Dox Prodrugs in a Neuroblastoma Tumor Model
    50,000.00 BAYSTATE HEALTH, INC. RPAP

TONYUSHKINA, KSENIA

  • Engaging School Nurses in Diabetes Care Team to Improve Diabetes Self-management Skills, Adherence, and Glycemic Control in Children with T1DM.
    49,991.00 BAYSTATE HEALTH, INC. RPAP

WASLICK, MD BRUCE

  • Improving Patient-Centered Outcomes for Adolescents with Depressive Illness through the Massachusetts Child Psychiatry Access Project (MCPAP)
    50,000.00 BAYSTATE HEALTH, INC. RPAP

WOZNIAK, JESSICA

  • UMASS CTTC Training Grant, new SAMHSA Subaward
    18,000.00 UNIV OF MA MEDICAL SCHOOL SUBST ABUSE MENTAL HLTH SVS AD

3rd Quarter (July-September 2016)

ANFANG, MD STUART

  • Imaging Dementia - Evidence for Amyloid Scanning (IDEAS) Study: A Coverage with Evidence Development Longitudinal Cohort Study
    67,500.00 AMERICAN COLLEGE OF RADIOLOGY

BLAIN, PETER

  • 21st Century Scholars FY16 Summer Program
    19,611.00 MA DEPT OF EDUCATION (DOE) US DEPT OF EDUCATION
  • FY17 WIOA
    45,000.00 REGION EMPL BOARD OF HAMDEN CTY US DEPT OF LABOR
  • 21st Century Scholars School Year FY17
    81,638.00 MA DEPT OF EDUCATION (DOE) US DEPT OF EDUCATION

CONROY, MD RUSHIK

  • A The Impact of Kurbo, a Pediatric Centered Weight Loss app, on BMI z Score Change in Obese Children and Adolescents
    6,000.00 KURBO HEALTH INC

DESABRAIS, MAUREEN

  • FY17 HIV Coordinator - Jail
    42,629.00 HAMPDEN COUNTY SHERIFF'S DEPT
  • FY17 HIV Educator - Jail
    53,589.00 HAMPDEN COUNTY SHERIFF'S DEPT

DESCHAINE, NORMAN

  • FY17 Medical Case Management
    497,109.00 MA DEPT OF PUBLIC HEALTH (DPH) DEPT HEALTH AND HUMAN SERVICES
  • FY17 PICSRT Budget 1
    813,693.15 MA DEPT OF PUBLIC HEALTH (DPH) DEPT HEALTH AND HUMAN SERVICES
  • FY17 ETI (PICSRT Budget 2)
    65,000.00 MA DEPT OF PUBLIC HEALTH (DPH) DEPT HEALTH AND HUMAN SERVICES
  • FY17 OBOT
    105,779.00 MA DEPT OF PUBLIC HEALTH (DPH) DEPT HEALTH AND HUMAN SERVICES

FLACK, MD JOSEPH

  • A Prospective, Multicenter, Non-Blinded, Non-Randomized Study of the Relay Pro thoracic Stent-Graft in Subjects with Thoracic Aortic Aneurysms and Penetrating Atherosclerotic Ulcers
    154,190.00 BOLTON MEDICAL INC.

HAESSLER MD, SARAH

  • FY17 Ebola Preparedness
    25,000.00 MA DEPT OF PUBLIC HEALTH (DPH) DEPT HEALTH AND HUMAN SERVICES

HEXDALL, MD AARON

  • MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department (MERCURY PE)
    17,760.00 JANSSEN PHARMACEUTICALS

LAGIER, CHRISTIAN

  • TechSpring Community Builder
    80,000.00 MASSACHUSETTS TECH COLLABORATIVE

LINDENAUER, MD PETER

  • The Relationship Between Early Pulmonary Rehabilitation and Outcomes After Hospitalization for COPD
    115,369.00 NAT. INSTITUTES OF HEALTH (NIH)

LOTFI, MD AMIR

  • A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients with Multivessel Coronary Artery Disease: Fractional Flow Reserve versus Angiography for Multivessel Evaluation (FAME) 3
    77,500.00 STANFORD UNIVERSITY MEDTRONIC, INC.

MADER, MD TIMOTHY

  • Evaluation of a simple tool for chest pain patient risk-stratification in North America
    49,994.00 AGENCY HC RESEARCH & QUALITY

MOORE, MD FRANKLIN

  • FilmArray Trend Research Project Study
    5,000.00 BIOFIRE DIAGNOSTICS, LLC

OH, MD DENNIS

  • A Randomised Controlled Study to Evaluate the Efficacy and Safety of Fibrin Sealant, Vapour Heated, Solvent/Detergent Treated (FS VH S/D 500 s apr) Compared to DuraSeal Dural Sealant as an Adjunct to Sutured Dural Repair in Cranial Surgery
    145,688.00 BAXTER

PACHECO, JASON

  • REB OJT Catalfamo
    5,952.00 REGION EMPL BOARD OF HAMDEN CTY US DEPT OF LABOR

PAREDES, REBEKAH

  • VOCA FY17 Trauma-focused
    323,067.00 MA OFFICE OF VICTIM ASSISTANCE
  • VOCA FY17 Homicide Bereavement
    185,839.00 MA OFFICE OF VICTIM ASSISTANCE
  • MACA FY17
    25,000.00 MASS CHILDREN'S ALLIANCE

RATHLEV, MD NIELS

  • Healing and preventing pain after injury: A randomized clinical trial of venlafaxine following motor vehicle collision
    12,573.00 RHODE ISLAND HOSPITAL MAYDAY FOUNDATION

SADOF, MD MATTHEW

  • FY17 Mass Start
    28,000.00 MA DEPT OF PUBLIC HEALTH (DPH) DEPT HEALTH AND HUMAN SERVICES

SARVET, BARRY MD

  • Partners in Care: Community-Based Implementation of Evidence-Based Treatment for Childhood Trauma
    399,887.00 SUBST ABUSE MENTAL HLTH SVS AD
  • MCPAP for Moms FY17
    93,550.00 MA BEHAVIORAL HLTH PARTNERSHIP
  • MCPAP FY17
    550,000.00 MA BEHAVIORAL HLTH PARTNERSHIP

SKIEST, MD DANIEL

  • FY17 NEAETC
    35,100.00 UNIV OF MA MEDICAL SCHOOL HRSA

STEINGRUB, MD JAY

  • A Randomized, Double-Blind, Placebo-Controlled, Four-Arm, Parallel-Group, Proof of Concept, and Dose-Finding Adaptive Phase 2a/2b Study to Investigate the Safety, Tolerability and Efficacy and Effect on Quality of Life of Human Recombinant Alkaline Phosph
    76,328.00 AM PHARMA
  • LOw Tidal volume Universal Support: Feasibility of RecrUitment for Interventional Trial
    41,912.15 MA GENERAL HOSPITAL NAT. HEART LUNG BLOOD INST.

TIDSWELL, MD MARK

  • A Phase 1b/2a, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-936559 in Subjects with Severe Sepsis
    118,996.00 BRISTOL-MYERS SQUIBB
  • EUPHORIA Evaluating the Use of Polymyxin B Hemoperfusion in a Prospective Non-controlled Trial In Adults
    254,834.00 SPECTRAL MEDICAL INC.

WYNNE, MONICA

  • FY17 ASPR
    26,687.08 FRCOG- FRANKLIN REG COUNCIL DEPT HEALTH AND HUMAN SERVICES

2nd Quarter (April - June 2016)

BOOS, MD STEPHEN

  • Project LAUNCH
    $69,969.00 MA DEPT OF PUBLIC HEALTH (DPH) SUBST ABUSE MENTAL HLTH SVS AD

CONROY, MD RUSHIKA

  • The Impact of Kurbo, a Pediatric Centered Weight Loss app, on BMI z Score Change in Obese Children and Adolescents
    $6,000.00 KURBO HEALTH INC N/A

LOTFI, MD AMIR

  • A MULTI-CENTER EVALUATION OF THE DELIVERY OF INTRACORONARY HYPEROXEMIC SUPERSATURATED OXYGEN THERAPY FOR 60 MINUTES IN ANTERIOR ACUTE MYOCARDIAL INFARCTION PATIENTS WITH SUCCESSFUL REPERFUSION (VIA PCI) LESS THAN OR EQUAL TO SIX HOURS AFTER SYMPTOM ONSET
    $36,524.00 THEROX INC. N/A

MCCANN, MD JOHN

  • WIRB: BI 1200.209 A Single Arm Phase IV Study of Afatinib in Elderly Patients with recurrent or Stage IV Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Have Common Epidermal Growth Factor Receptor (EGFR) mutations (Exon 19 Deletions or Exon 21 L858R Subs
    $45,000.00 BOEHRINGER INGELHEIM

MERTENS, MD WILSON

  • WIRB: Galera Therapeutics, Inc. GT-201 A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Trial of the Effects of Intravenous GC4419 on the Incidence and Duration of Severe Oral Mucositis (OM) in Patients Receiving Post-Operative or De
    $60,000.00 GALERA THERAPEUTICS, INC.

PACHECO, JASON

  • REB OJT Catalfamo 5,952.00 REGION EMPL BOARD OF HAMDEN CTY US DEPT OF LABOR

PACHECO, JASON REB OJT March 2016 RN Group
$51,840.00 REGION EMPL BOARD OF HAMDEN CTY US DEPT OF LABOR

PAREDES, REBEKAH

  • NCA 2016
    $9,000.00 MASS CHILDREN'S ALLIANCE NATIONAL CHILDREN'S ALLIANCE

QUIZON, MD ANNABELLE

  • Participation in the Cystic Fibrosis Patient Registry
    $60,680.00 CYSTIC FIBROSIS FOUNDATION N/A

SHENBERGER, MD JEFFREY

  • A MULTICENTER, DOUBLE BLIND, RANDOMIZED, SINGLE DOSE, ACTIVE-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF SYNTHETIC SURFACTANT (CHF 5633) IN COMPARISON TO PORCINE SURFACTANT (PORACTANT ALFA, CUROSURF®) IN THE TREATMENT OF PRETERM NEONATES WI
    $89,964.00 CHIESI FARMACEUTICI S.P.A. N/A

SINGH, MD RACHANA

  • A Phase Ib/IIa Randomized, Placebo Controlled Study of the Safety and Efficacy of Once Daily Dosing of STP206 in Premature Very Low Birth Weight and Extremely Low Birth Weight Neonates
    $280,800.00 SIGMA-TAU PHARMACEUTICALS, INC. N/A

SKIEST, MD DANIEL

  • GS-US-380-1489: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults
    $110,075.00 GILEAD SCIENCES, INC N/A
  • Cooperative Re-engagement Controlled Trial (CoRECT)
    $23,300.00 MA DEPT OF PUBLIC HEALTH (DPH)

1st Quarter (January - March 2016)

Iglesias Lino MD, Laura

  • Practice Change Leaders
    $44,920, Univ Colorado Denver, The Atlantic Philanthropies

Deschaine, Norman

  • 2016 Ryan White
    $425,326, Holyoke Health Center, Inc. Health Resources & Svsc Admin
  • 2016 Migrant Farmworkers
    $7,810, MA League Community Hlth Cntrs, Dept Health And Human Services

Friedmann, MD Peter

  • Distress Tolerance And Hiv Prevention With Xr-Ntx Initiation In Opioid Dependence
    $5,881, Rhode Island Hospital, Nat Inst On Drug Abuse

Nahmias, MD Jeffry

  • A Phase Iv, Multicenter, Prospective, Randomized, Controlled Clinical Study To Compare The Irrisept System Versus Standard Of Care (Soc) On The Prevalence Of Surgical Site Infection (Ssi) In Patients With Abdominal Trauma Or Acute Surgical Abdomen
    $131,250, N/A

Ali, MD Syed

  • Wirb: Tg Therapeutics, Inc. Utx-Ib-301 A Phase 3, Randomized, Study To Assess The Efficacy And Safety Of Ublituximab In Combination With Ibrutinib Compared To Ibrutinib Alone, In Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia
    $150,000, Tg Therapeutics, Inc.

Rousou, MD John

  • A Randomized, Double-Blind, Placebo Controlled, Phase 2 Study To Evaluate The Efficacy And Safety Of Qpi-1002 For The Prevention Of Acute Kidney Injury In Subjects At High Risk For Aki Following Cardiac Surgery
    $160,720, Quark Pharmaceutical Inc.

Lee, MD Patrick

  • A Health Economic Study Of Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Studies To Investigate The Efficacy And Safety Of The Xaracoll® Bupivacaine Implant (300 Mg Bupivacaine Hydrochloride) After Open Laparotomy Hernioplasty
    $4,200, Innocoll Technologies, Ltd

Giugliano, MD Gregory

  • Twilight Study: Ticagrelor With Aspirin Or Alone In High-Risk Patients After Coronary Intervention
    $112,500, Mt. Sinai School Of Medicine, Bayer Corporation

Makari-Judson, MD Grace

  • Roh Crispr Editing Of Primary Breast Cells Tools For Precision Therapeutics And Diagnostics
    $25,000, Baystate Health, Rays Of Hope Ctr Br Ca Rsrch
  • Roh Describing Eye Movement Changes Associated With Cancer-Related Fatigue Using Wearable Eye Technology $49,849, Baystate Health, Rays Of Hope Ctr Br Ca Rsrch
  • Roh Anti-Parp1 Shrna-Delivering Bacteria To Treat Triple Negative Breast Cancer
    $25,000, Baystate Health, Rays Of Hope Ctr Br Ca Rsrch
  • Roh Environmental Estrogens, Primary Breast Explants, And Dna Methylation Elucidating Mechanisms Of Individual Susceptibility
    $50,000, Baystate Health, Rays Of Hope Ctr Br Ca Rsch
  • Roh Bpa Phthalates Effects On Breast Denisty In Young Women
    $25,000, Baystate Health, Rays Of Hope Ctr Br Ca Rsrch

Tidswell, MD Mark

  • A Double-Blind, Randomised, Placebo-Controlled, Phase 2b/3 Adaptive Clinical Trial Investigating The Efficacy And Safety Of Selepressin As Treatment For Patients With Vasopressor-Dependent Septic Shock
    $85,854, Ferring Pharmaceuticals A/S

2015

4th Quarter (October - December 2015)

ENGELMAN, MD RICHARD

  • CytoSorb® Reduction of Free Hemoglobin during Cardiac Surgery (REFRESH Trial)
    $35,305, CYTOSORBENTS INC.

FRIEDMANN, MD PETER

  • Impact of health reform on outpatient substance abuse treatment programs
    $310,272, NIDA
  • Implementation to motivate physician response to opiod dependence in HIV setting
    $868,936, NIDA
  • Supplement: Implementation to motivate physician response to opiod dependence in HIV setting
    $150,000, NAT INST ON DRUG ABUSE

HAESSLER MD, SARAH

  • Ebola Preparedness and Response Activities Grant FY16
    $25,000,MA DEPT OF PUBLIC HEALTH, DEPT HEALTH AND HUMAN SERVICES

HARMANLI, MD OZ

  • A Post-Market Evaluation of the Altis Single Incision Sling System versus Transobturator or Retropubic Mesh Sling in the Treatment of Female Stress Urinary Incontinence (Altis 522 Study)
    $100,000, COLOPLAST CORP.

KATTAN, MD DAVID

  • PostFellowship Family Planning Salary Support
    $53,880, ANONYMOUS FOUNDATION

LEE, MD PATRICK

  • A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of the XaraColl® Bupivacaine Implant (300 mg Bupivacaine Hydrochloride) After Open Laparotomy Hernioplasty
    $138,840, INNOCOLL TECHNOLOGIES, LTD
  • A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline IV/PO to Linezolid IV/PO for Treating Adult Subjects with Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
    $74,722,  PARATEK PHARMA LLC

MAKARI-JUDSON, MD GRACE

  • M12-914 A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2-Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer
    $309,000, ABBVIE, INC.

PACOCHA, DARLENE

  • Aerogen Bench Study
    $15,000, AEROGEN LIMITED

ROUSOU, MD JOHN

  • A Prospective, Randomized, Controlled Study to Evaluate the Effectiveness and Safety of CELSTAT as an Adjunct to Hemostasis for Tissue Bleeding in Cardiothoracic, General and Vascular Surgery
    $109,219, BAXTER

STEINGRUB, MD JAY

  • Reevaluation of Systemic Early Neuromuscular Blockade (ROSE)
    $166,314, MA GENERAL HOSPITAL, NAT.HEART LUNG BLOOD INST.

SUMMERS, MANDI

  • Child Passenger Safety Training and Administration Program FY16
    $150,000, MA EXEC OFFICE PUBLIC SAFETY, US DEPT OF HIGHWAY SAFETY